期刊文献+

高龄患者原发性肝癌的循证治疗

Therapy strategy of evidence-based practice for the aged patient with primary liver cancer
下载PDF
导出
摘要 目的:借助循证医学的方法为高龄患者原发性肝癌确定治疗目标及治疗方案。方法:在充分评估患者病情的基础上根据PICO原则构建临床问题,采用EBM五步法确定检索策略。检索Embase、Cochrane library、Pub Med、CHKD、万方数据库,检索时间截至2014年9月。查找与高龄原发性肝癌患者治疗相关的系统评价/Meta分析、随机对照试验,对所获证据进行评价,并结合患者家属意愿制定治疗方案。结果:共检出并筛选出与原发性肝癌相关的随机对照试验7篇,系统评价/Meta分析4篇,通过对检索结果进行分析,为患者制定合理的治疗方案,经1年随访证实该方案对患者有满意的疗效。结论:采用循证治疗方法,为原发性肝癌高龄患者制定合理治疗方案,可取得满意的效果。 Objective: To formulate an evidence- based treatment plan for the aged patient with primary carcinoma of the liver. Methods: The search strategy was determined by EBM. Based on the PICO principle,the clinical problems were put forward after full evaluation of patients ' conditions. We searched the Embase( 1990- 2014),Cochrane library( Issue 9,2014),Pub Med( 1980- 2014),CHKD and CNKI periodical database to identify systematic reviews( SRs),randomized controlled trails( RCTs) involving the treatment for the aged patient with primary carcinoma of the liver. All the collected evidence was critically assessed. Patient preferences was also taken into consideration in the decision- making treatment. Results: A total of 7 RCTs,4 systematic reviews / Meta- analyses were identified.A rational treatment plan was made upon a serious evaluation of the data and the opinion of the patient. After one year of follow- up,the plan was proved optimal. Conclusion: The treatment plan according to evidence- based method for the aged patient with primary carcinoma of the liver can effectively improve the therapeutic efficacy.
出处 《现代肿瘤医学》 CAS 2017年第4期581-583,共3页 Journal of Modern Oncology
基金 中国人民解放军总后卫生部保健专项课题(编号:15BJZ06)
关键词 高龄 肝肿瘤 原发性肝癌 循证治疗 aged hepatoma primary carcinoma of the liver evidence-based treatment
  • 相关文献

参考文献4

二级参考文献32

  • 1向昕,刘志伟,史宪杰,顾万清.经导管肝动脉化疗栓塞后肝癌微血管密度及血管内皮生长因子的表达[J].解放军医学杂志,2005,30(1):45-45. 被引量:8
  • 2陈晓明,罗鹏飞.肝癌经导管肝动脉化疗性栓塞存在的问题与对策[J].实用医学杂志,2007,23(6):786-787. 被引量:14
  • 3Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics 2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 4Llovet JM,Schwartz M,Mazzaferro V,et al.Resection and liver transplantation for hepatocellular carcinoma[J].Semin Liver Dis,2005,25(2):181-200.
  • 5Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
  • 6Higgins JPT,Green S.The Cochrane Collaboration.Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2[EB/OL].[2009-9-20].http://www.cochrane-handbook.org.
  • 7Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
  • 8Wu SH,Chen JJ,Andrzej K,et al.Incidence and risk of hypertension with sorafenib in patients with cancer:a systematic review and meta-analysis[J].Lancet Oncol,2008,9(2):117-123.
  • 9Melman A,Grim CE,Weinberger MH,et al.Increased incidence of renal cell carcinoma with hypertension[J].J Urol,1977,118(4):531-532.
  • 10管考鹏,马建辉,孙燕.索拉非尼的毒副作用及处理[J].癌症进展,2007,5(4):370-373. 被引量:39

共引文献1022

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部